The purpose of this study is to compare clinical, economical and quality of life (QOL) outcomes in patients living with HIV on zidovudine/stavudine regimen and tenofovir regimen. This study will be an unblinded randomized trial. The first step will be empirical data collection for one year for calculating the incremental cost effectiveness ratio (ICER). The second step will be to perform a simulation model for calculating long term ICER.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Viral suppression
Timeframe: End of follow-up : end of 12th Month
Change in CD4 levels
Timeframe: End of Months 6 and 12
Drug related toxicity
Timeframe: Months : 1,2,3,4,5,6,7,8,9,10,11,12
opportunistic infections
Timeframe: Months: 1,2,3,4,5,6,7,8,9,10,11,12
Direct costs
Timeframe: Months: 1,2,3,4,5,6,7,8,9,10,11,12
Quality of life
Timeframe: Month 1 and end of months 4,8 and 12